Replies to post #830 on Revance Therapeutics Inc (RVNC)

[dewophile]

Efficacy (ASPEN-1)—placebo comparator; 300 patients; single-injection; 36w observation; expected completion Sep 2020

This is a hugely important readout for the company, and it's not that far away. Unlike plantar fasc. which is a high risk trial, this is going to make or break the valuation of the company truly, and everything between now and then is mostly noise (as long as they can get that BLA done by year end)
JMO for all those bitching about the share price

[jmkobers]

Hey Dew:

That was my point, those 2 and a bunch of others as well.

In message #msg-146260318 you said,

All told, the above is (IMO) a well-conceived plan to support multiple aesthetic and therapeutic indications without incurring unduly high clinical-trial expenses.

So do you believe the company can continue to burn 160 million yearly PLUS the added expenses of a go it alone strategy related to cosmetic launch in US and still be a good investment in the next 2-3 years for existing shareholders? Doesn't something have to give here? Or is your horizon long enough such that the 2-3 time frame is not major concern. If so, I am sure in the wrong investment. I am here to make money, preferably before I am 6 feet under

[DewDiligence]

RVNC completes enrollment—(301 patients)—in ASPEN-1 CD efficacy trial:

https://investors.revance.com/news-releases/news-release-details/revance-completes-enrollment-aspen-1-phase-3-pivotal-trial

Top line data is expected in 2H20.

See #msg-148887973 for related info on RVNC’s CD program.

[DewDiligence]

ASPEN-OLS phase-3 CD trial is fully enrolled, according to today’s 1Q20 CC:

#msg-155501147